Gastric Inhibitory Polypeptide Receptor - Drugs In Development, 2021
Gastric Inhibitory Polypeptide Receptor - Drugs In Development, 2021
SUMMARY
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 26 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Gastric Inhibitory Polypeptide Receptor - Drugs In Development, 2021, outlays comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Glucose-dependent insulinotropic polypeptide receptor (GIPR) is a transmembrane protein in humans which is encoded by the GIPR gene. GIPR is expressed on pancreatic beta-cells which lead to activation and release of insulin. The transcription of this protein is positively controlled by glucose molecules. GIPR is expressed in higher levels when glucose is in higher concentration. The ligand which binds to GIPR is glucose-dependent insulinotropic polypeptide (GIP) also known as gastric inhibitory polypeptide. Glucose-dependent insulinotropic polypeptide is released from the duodenum and small intestine. GIP binds to GIPR though hydrophobic interactions and triggering activation of G protein-coupled receptors, which in turn causes an enzymatic cascade resulting in the increased secretion of insulin. Endogeonous ligands for the receptor include oleylethanolamide and lysophosphatidylcholine. The cause of type 2 diabetes is due to the inability of GIP to bind properly to GIPR. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 8, 8, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Central Nervous System, Musculoskeletal Disorders, Cardiovascular and Respiratory which include indications Obesity, Type 2 Diabetes, Diabetes, Non-Alcoholic Steatohepatitis (NASH), Alzheimer's Disease, Non Alcoholic Fatty Liver Disease (NAFLD), Parkinson's Disease, Cardiovascular Risk Factors, Circadian Rhythm Sleep Disorders, Diastolic Heart Failure, Fibrosis, Idiopathic Pulmonary Fibrosis, Osteoporosis, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Sclerosing Cholangitis, Type 1 Diabetes (Juvenile Diabetes) and Unspecified Metabolic Disorders.
Furthermore, this report also reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 26 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Gastric Inhibitory Polypeptide Receptor - Drugs In Development, 2021, outlays comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Glucose-dependent insulinotropic polypeptide receptor (GIPR) is a transmembrane protein in humans which is encoded by the GIPR gene. GIPR is expressed on pancreatic beta-cells which lead to activation and release of insulin. The transcription of this protein is positively controlled by glucose molecules. GIPR is expressed in higher levels when glucose is in higher concentration. The ligand which binds to GIPR is glucose-dependent insulinotropic polypeptide (GIP) also known as gastric inhibitory polypeptide. Glucose-dependent insulinotropic polypeptide is released from the duodenum and small intestine. GIP binds to GIPR though hydrophobic interactions and triggering activation of G protein-coupled receptors, which in turn causes an enzymatic cascade resulting in the increased secretion of insulin. Endogeonous ligands for the receptor include oleylethanolamide and lysophosphatidylcholine. The cause of type 2 diabetes is due to the inability of GIP to bind properly to GIPR. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 8, 8, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Central Nervous System, Musculoskeletal Disorders, Cardiovascular and Respiratory which include indications Obesity, Type 2 Diabetes, Diabetes, Non-Alcoholic Steatohepatitis (NASH), Alzheimer's Disease, Non Alcoholic Fatty Liver Disease (NAFLD), Parkinson's Disease, Cardiovascular Risk Factors, Circadian Rhythm Sleep Disorders, Diastolic Heart Failure, Fibrosis, Idiopathic Pulmonary Fibrosis, Osteoporosis, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Sclerosing Cholangitis, Type 1 Diabetes (Juvenile Diabetes) and Unspecified Metabolic Disorders.
Furthermore, this report also reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)
- The report reviews Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics and enlists all their major and minor projects
- The report assesses Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Overview
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Companies Involved in Therapeutics Development
Amgen Inc
Antag Therapeutics ApS
Bainan Biotech ApS
Carmot Therapeutics Inc
D&D Pharmatech Co Ltd
Eli Lilly and Co
Great Bay Bio Holdings Ltd
Hanmi Pharmaceuticals Co Ltd
Kariya Pharmaceuticals IVS
Longevity Biotech Inc
Novo Nordisk AS
Zealand Pharma AS
Zhejiang Doer Biologics Corp
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Drug Profiles
(semaglutide + GIP analogue) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-133 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Agonize GLP-1R, GIPR and GLR for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-868 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DAJC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DD-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DR-10624 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DR-10625 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DR-10627 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Agonize GIP and GLP-2 for Osteoporosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-15211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBT-6030 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3437943 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3493269 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3537021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Antagonize GIPR for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Activate GIPR for Type I Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GIPR and GLP1R for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide 1 for Type 2 Diabetes, Obesity and Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide 1 to Agonize GIPR and GLP1R for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide 1 to Agonize GIPR for Alzheimer's Disease and Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize GIPR and GLP1R for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize GIP, GR and GLP-1R for Gastrointestinal and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tirzepatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZP-6590 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Dormant Products
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Discontinued Products
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Product Development Milestones
Featured News & Press Releases
Jun 29, 2021: Latest data from SURPASS trials demonstrate Tirzepatide provided meaningful blood sugar reductions and weight loss
Jun 26, 2021: Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes
Jun 25, 2021: Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes
Jun 11, 2021: Lilly announces webcast to provide diabetes portfolio update at ADA
May 21, 2021: Lilly’s tirzepatide meets endpoints in type 2 diabetes trial
May 04, 2021: Carmot Therapeutics announces investigational new drug (IND) clearance for CT-868, a dual GLP-1 and GIP receptor modulator for the treatment of overweight and obese patients with type 2 diabetes
Mar 05, 2021: Lilly’s tirzepatide leads to body weight reductions in type 2 diabetes trial
Feb 17, 2021: Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program
Feb 17, 2021: Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program
Dec 14, 2020: Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes
Dec 10, 2020: Lilly reports positive data from trial of tirzepatide for type 2 diabetes
Nov 11, 2020: Lilly announces webcast to provide an overview of Tirzepatide Phase 3 clinical program
Jul 22, 2020: FDA grants fast track designation for Hanmi LAPSTriple agonist
Jun 10, 2020: Lilly begins dosing in cardiovascular outcomes trial of tirzepatide
Mar 11, 2020: Hanmi's NASH treatment wins more orphan drug status
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Overview
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Companies Involved in Therapeutics Development
Amgen Inc
Antag Therapeutics ApS
Bainan Biotech ApS
Carmot Therapeutics Inc
D&D Pharmatech Co Ltd
Eli Lilly and Co
Great Bay Bio Holdings Ltd
Hanmi Pharmaceuticals Co Ltd
Kariya Pharmaceuticals IVS
Longevity Biotech Inc
Novo Nordisk AS
Zealand Pharma AS
Zhejiang Doer Biologics Corp
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Drug Profiles
(semaglutide + GIP analogue) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-133 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Agonize GLP-1R, GIPR and GLR for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-868 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DAJC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DD-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DR-10624 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DR-10625 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DR-10627 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Agonize GIP and GLP-2 for Osteoporosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-15211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBT-6030 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3437943 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3493269 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3537021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Antagonize GIPR for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Activate GIPR for Type I Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GIPR and GLP1R for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide 1 for Type 2 Diabetes, Obesity and Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide 1 to Agonize GIPR and GLP1R for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide 1 to Agonize GIPR for Alzheimer's Disease and Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize GIPR and GLP1R for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize GIP, GR and GLP-1R for Gastrointestinal and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tirzepatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZP-6590 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Dormant Products
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Discontinued Products
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Product Development Milestones
Featured News & Press Releases
Jun 29, 2021: Latest data from SURPASS trials demonstrate Tirzepatide provided meaningful blood sugar reductions and weight loss
Jun 26, 2021: Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes
Jun 25, 2021: Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes
Jun 11, 2021: Lilly announces webcast to provide diabetes portfolio update at ADA
May 21, 2021: Lilly’s tirzepatide meets endpoints in type 2 diabetes trial
May 04, 2021: Carmot Therapeutics announces investigational new drug (IND) clearance for CT-868, a dual GLP-1 and GIP receptor modulator for the treatment of overweight and obese patients with type 2 diabetes
Mar 05, 2021: Lilly’s tirzepatide leads to body weight reductions in type 2 diabetes trial
Feb 17, 2021: Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program
Feb 17, 2021: Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program
Dec 14, 2020: Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes
Dec 10, 2020: Lilly reports positive data from trial of tirzepatide for type 2 diabetes
Nov 11, 2020: Lilly announces webcast to provide an overview of Tirzepatide Phase 3 clinical program
Jul 22, 2020: FDA grants fast track designation for Hanmi LAPSTriple agonist
Jun 10, 2020: Lilly begins dosing in cardiovascular outcomes trial of tirzepatide
Mar 11, 2020: Hanmi's NASH treatment wins more orphan drug status
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Amgen Inc, 2021
Pipeline by Antag Therapeutics ApS, 2021
Pipeline by Bainan Biotech ApS, 2021
Pipeline by Carmot Therapeutics Inc, 2021
Pipeline by D&D Pharmatech Co Ltd, 2021
Pipeline by Eli Lilly and Co, 2021
Pipeline by Great Bay Bio Holdings Ltd, 2021
Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021
Pipeline by Kariya Pharmaceuticals IVS, 2021
Pipeline by Longevity Biotech Inc, 2021
Pipeline by Novo Nordisk AS, 2021
Pipeline by Zealand Pharma AS, 2021
Pipeline by Zhejiang Doer Biologics Corp, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Amgen Inc, 2021
Pipeline by Antag Therapeutics ApS, 2021
Pipeline by Bainan Biotech ApS, 2021
Pipeline by Carmot Therapeutics Inc, 2021
Pipeline by D&D Pharmatech Co Ltd, 2021
Pipeline by Eli Lilly and Co, 2021
Pipeline by Great Bay Bio Holdings Ltd, 2021
Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021
Pipeline by Kariya Pharmaceuticals IVS, 2021
Pipeline by Longevity Biotech Inc, 2021
Pipeline by Novo Nordisk AS, 2021
Pipeline by Zealand Pharma AS, 2021
Pipeline by Zhejiang Doer Biologics Corp, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021
